Impact of cilostazol on clinical and angiographic outcome after primary stenting for acute myocardial infarction.

Author(s): Ochiai M, Eto K, Takeshita S, Yokoyama N, Oshima A, Kondo K, Sato T, Isshiki T

Affiliation(s): Department of Medicine (Cardiology), Teikyo University School of Medicine, Tokyo, Japan. mochiai@med.teikyo-u.ac.jp

Publication date & source: 1999-11-01, Am J Cardiol., 84(9):1074-6, A6, A9.

Publication type: Clinical Trial; Randomized Controlled Trial

Cilostazol, an antiplatelet drug that also may inhibit smooth muscle proliferation, was given together with aspirin after primary stenting to treat patients with acute myocardial infarction. In a randomized controlled trials of 50 patients, clinical and angiographic outcome at 6 months was significantly improved with cilostazol, depicting a significantly smaller late loss and/or loss index.